Published in Vaccine Weekly, June 28th, 1999
The technology licensed by Inhibitex is based upon research conducted by Margaret Hostetter, MD, while at the University of Minnesota, Department of Pediatric Infectious Diseases. Based upon the discoveries of Hostetter, Inhibitex expects to develop a vaccine that will eliminate or reduce the number of C. albicans organisms present within high-risk individuals. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.